Walleye Capital LLC decreased its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) by 41.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 64,050 shares of the biopharmaceutical company’s stock after selling 44,441 shares during the period. Walleye Capital LLC owned approximately 0.11% of Vanda Pharmaceuticals worth $724,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its holdings in shares of Vanda Pharmaceuticals by 134.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 8,540 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 4,900 shares in the last quarter. CI Investments Inc. acquired a new stake in shares of Vanda Pharmaceuticals during the 1st quarter valued at $107,000. Wedge Capital Management L L P NC acquired a new stake in shares of Vanda Pharmaceuticals during the 1st quarter valued at $117,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 1st quarter valued at $119,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Vanda Pharmaceuticals during the 4th quarter valued at $168,000. Institutional investors own 99.42% of the company’s stock.
Analysts Set New Price Targets
Separately, StockNews.com raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 3rd.
Insiders Place Their Bets
Vanda Pharmaceuticals Stock Up 1.1 %
NASDAQ VNDA opened at $9.94 on Wednesday. The company has a market cap of $562.22 million, a price-to-earnings ratio of 49.70 and a beta of 0.47. Vanda Pharmaceuticals Inc. has a twelve month low of $9.24 and a twelve month high of $21.44. The business’s fifty day moving average is $10.56 and its 200 day moving average is $10.65.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.